Live Investor Briefing – Prescient Therapeutics

Prescient Therapeutics (ASX: PTX)
Live Investor Briefing

Register for an upcoming webcast

Please join Prescient Therapeutics CEO Steven Yatomi-Clarke for a special live investor briefing.

Event Details:

Register for an upcoming webcast

In the session, Steven will discuss:

  • PTX’s three new next-gen CAR-T programs in hematological and solid cancers with massive addressable markets and unmet needs
  • Using OmniCAR’s unique features to create therapies where current generation CAR-Ts have struggled
  • Additional follow-on research programs will also demonstrate OmniCAR’s many unique features and properties and create future clinical candidates

This is a live and interactive session, you simply need an internet connection to participate. Don’t miss out, spots are limited – This is a FREE event.

Book Your Spot

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.

What is a 708 investor?


Steven Yatomi-Clarke (Speak feature)

Steven Yatomi-Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.